Eli Lilly and Company and Boehringer Ingelheim’s Jardiance (empagliflozin) has obtained priority review from the US Food and Drug Administration (FDA) to treat adults with heart failure regardless
French company Valneva has received European Commission (EC) approval for an agreement to supply the company’s inactivated Covid-19 vaccine candidate, VLA2001. Under the terms of the deal, the
AbbVie has extended a collaboration agreement with the University of Chicago until 2025 to support preclinical research in oncology. Till date, the partners have been working together on
With this round, the biotechnology firm has raised more than $300m so far. The funding round was led by Ally Bridge Group, TCG Crossover, and Temasek. Among the
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314. The new gene
Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma. The latest move
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD). It has been recommended
EffRx Pharmaceuticals has received marketing authorisation from Swissmedic for Bronchitol to treat cystic fibrosis (CF) in adults and in children aged six years and above. Developed by Australian
Novavax has completed the rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its Covid-19 vaccine candidate, NVX-CoV2373. The company has submitted all
SNX281 is Stingthera’s small molecule agonist of the Stimulator of Interferon Genes (STING) protein. An anti-programmed death receptor-1 (anti-PD-1) therapy, Keytruda is a registered trademark of Merck &
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.